Larix laricina, an Antidiabetic Alternative Treatment from the Cree of Northern Quebec Pharmacopoeia, Decreases Glycemia and Improves Insulin Sensitivity In Vivo

Table 2

Effects of HFD and L. laricina administration on hepatic and muscular triglyceride accumulation.

	Prevention protocol			Treatment protocol
	DIO	L. laricina	L. laricina	DIO	L. laricina	L. laricina
		125 mg/kg	250 mg/kg		125 mg/kg	250 mg/kg
Liver TG levels (mg/g total liver)	331±54	407±47	374±52	1041±173	919±240	1138±118
Muscle TG levels (μg/mg)	84±12	60±6	65±8	212±29	224±80	255±33

The colorimetric dosage of TG levels in both the liver and muscle was determined using a commercial kit (as described in detail in Section 2.8). Measurements were obtained after 8 (prevention) or 16 (treatment) weeks of administration with either HFD (DIO) or L. laricina at 125 or 250 mg/kg, which was incorporated in the HFD for 8 weeks in the prevention protocol and for the last 8 of 16 weeks in the treatment protocol. All values represent the mean ± SEM (prevention protocol DIO = 11; L. laricina 125 = 13; L. laricina 250 = 13, and for the treatment protocol DIO = 7; L. laricina 125 = 5; L. laricina 250 = 8).